Table 5.

Adjusted risk of inappropriate empiric therapy, hospital mortality, excess LOS and costs

	Marginal effect, CSE	Marginal effect, CRE	Adjusted relative risk ratio/excess days or costs (95% confidence interval)	P-value
Risk of IET
Parse Model	11.8%	47.7%	3.95 (3.51, 4.46)	<0.001
Propensity score (based on 100% CRE cases matched to CSE 1:1)	13.1%	55.8%	4.27 (3.64, 5.00)	<0.001
Non-parse model	11.9%	47.7%	4.00 (3.48, 4.59)	<0.001
	Marginal effect, non-IET	Marginal effect, IET	Adjusted relative risk ratio/excess days or costs (95% confidence interval)	P-value
Risk of death
Hierarchical model	9.8%	11.0%	1.12 (1.03, 1.23)	0.013
Propensity score (based on 96.4% IET cases matched to non-IET 1:1)	10.5%	11.9%	1.13 (1.01, 1.27)	0.030
Length of stay (days)
Hierarchical model	8.2	13.4	5.2 (4.8, 5.6)	<0.001
Propensity score (based on 96.4% IET cases matched to non-IET 1:1)	9.6	14.6	5.0 (4.4, 5.6)	<0.001
Hospital costs
Hierarchical model	$20,508	$30,819	$10,312 ($9497, $11,126)	<0.001
Propensity score (based on 96.4% IET cases matched to non-IET 1:1)	$22,005	$32,837	$10,831 ($9254, $12,409)	<0.001

IET inappropriate empiric therapy, CSE carbapenem sensitive Enterobacteriaceae, CRE carbapenem resistant Enterobacteriaceae